METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE | A204144 | PH HEALTH LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Merck Sharp & Dohme Corp. v. Anchen Pharmaceuticals, Inc., et al. 1 patentANDA 204144metformin hydrochloride; sitagliptin phosphate | D. Del. | 2019-02-13 | Terminated 2021-03-02 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.
PH Health changed Sitagliptin and Metformin Hydrochloride (NDA 204144) from discontinued status to prescription drug status.
Old: DISCN
New: RX
Sitagliptin and metformin hydrochloride (PH Health, NDA 204144) received a therapeutic equivalence rating of AB, indicating bioequivalence to the reference product.
New: AB
PH Health's sitagliptin phosphate and metformin hydrochloride product (NDA 204144, supplement 002) received an AB therapeutic equivalence code designation.
New: AB
PH Health's sitagliptin phosphate and metformin hydrochloride combination (NDA 204144, supplement 003) received an AB therapeutic equivalence rating.
New: AB
PH Health changed SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (metformin hydrochloride; sitagliptin phosphate) from discontinued to active prescription drug status for NDA 204144.
Old: DISCN
New: RX
Sitagliptin and metformin hydrochloride (metformin hydrochloride; sitagliptin phosphate) application 204144-003 by PH Health transitioned from discontinued to active prescription drug status.
Old: DISCN
New: RX